Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023 8:00 AM
NEWARK, Calif., March 7, 2023 -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be presenting a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 11:20 a.m. ET, in a virtual format.